[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,645,484
  • Shares Outstanding, K 166,676
  • Annual Sales, $ 1,476 M
  • Annual Income, $ 241,660 K
  • EBIT $ 204 M
  • EBITDA $ 231 M
  • 60-Month Beta 0.34
  • Price/Sales 5.87
  • Price/Cash Flow 31.02
  • Price/Book 4.93

Options Overview Details

View History
  • Implied Volatility 54.52% (+1.82%)
  • Historical Volatility 40.27%
  • IV Percentile 69%
  • IV Rank 22.42%
  • IV High 112.83% on 07/17/25
  • IV Low 37.67% on 09/09/25
  • Expected Move (DTE 2) 2.14 (4.15%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 339
  • Volume Avg (30-Day) 1,193
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 24,405
  • Open Int (30-Day) 20,604
  • Expected Range 49.46 to 53.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 5
  • High Estimate $0.01
  • Low Estimate $-0.09
  • Prior Year $0.52
  • Growth Rate Est. (year over year) -107.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.34 +19.06%
on 06/15/26
55.67 -7.31%
on 07/07/26
+7.32 (+16.53%)
since 06/12/26
3-Month
32.83 +57.15%
on 04/27/26
55.67 -7.31%
on 07/07/26
+17.73 (+52.35%)
since 04/14/26
52-Week
25.17 +105.05%
on 09/08/25
55.67 -7.31%
on 07/07/26
+21.91 (+73.80%)
since 07/14/25

Most Recent Stories

More News
Alkermes to Report Second Quarter Financial Results on July 28, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results....

ALKS : 51.60 (-0.52%)
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

— First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy...

ALKS : 51.60 (-0.52%)
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to...

ALKS : 51.60 (-0.52%)
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1),...

ALKS : 51.60 (-0.52%)
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

— 26 Abstracts Accepted Demonstrate Alkermes’ Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia — — Detailed Positive...

ALKS : 51.60 (-0.52%)
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47 th Annual Global Healthcare Conference on Wednesday, June...

ALKS : 51.60 (-0.52%)
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —

ALKS : 51.60 (-0.52%)
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder,...

ALKS : 51.60 (-0.52%)
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported...

ALKS : 51.60 (-0.52%)
Alkermes: Q1 Earnings Snapshot

Alkermes: Q1 Earnings Snapshot

ALKS : 51.60 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 53.80
2nd Resistance Point 52.98
1st Resistance Point 52.29
Last Price 51.60
1st Support Level 50.78
2nd Support Level 49.97
3rd Support Level 49.28

See More

52-Week High 55.67
Last Price 51.60
Fibonacci 61.8% 44.02
Fibonacci 50% 40.42
Fibonacci 38.2% 36.82
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.